A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study

cited authors

  • Prados, MD; Lamborn, K; Yung, WKA; Jaeckle, K; Robins, HI; Mehta, M; Fine, HA; Wen, PY; Cloughesy, T; Chang, S; Nicholas, MK; Schiff, D; Greenberg, H; Junck, L; Fink, K; Hess, K; Kuhn, J

keywords

  • CHEMOTHERAPY
  • Clinical Neurology
  • Life Sciences & Biomedicine
  • METABOLITE
  • Oncology
  • Science & Technology
  • phase 2

start page

  • 189

end page

  • 193

issue

  • 2